 Clinical Oncology News | Everolimus Touted As Game Changer In Breast Cancer Clinical Oncology News Adding everolimus (Afinitor, Novartis) to exemestane therapy improved progression-free survival (PFS) by four months compared with therapy with exemestane alone, according to an interim analysis of the Phase III trial BOLERO-2 (Breast Cancer Trials of ... |
